Cancer datasets and tissue pathways

The College's Datasets for Histopathological Reporting on Cancers are vital for standardising cancer reporting methods among pathologists. These datasets define the range of acceptable practice in handling pathology specimens, and enhance cancer diagnosis and treatment quality. Cancer datasets encompass structured collections of data related to cancer patients.

Tissue pathways are instrumental in defining best practices when handling pathology specimens from patients who do not have cancer. These guidelines are pivotal in raising the bar for healthcare standards in pathology.

Joint Statement: FIGO 2026 Staging of Gestational Trophoblastic Neoplasia

The Royal College of Pathologists (RCPath), British Gynaecological Cancer Society (BGCS) and British Association of Gynaecological Pathologists (BAGP) support the implementation of the new 2026 FIGO staging system for gestational trophoblastic neoplasia (GTN).

To ensure consistency in clinical practice and, importantly, comparability of national data, audit and research datasets, we recommend a coordinated UK implementation date of:

1 January 2027 – for patients diagnosed on or after this date.

The 2026 FIGO staging system may be used clinically before this date where considered appropriate. However, for national data collection and reporting, cases diagnosed before 1 January 2027 should continue to be recorded using the previous FIGO staging system.

A common implementation date will facilitate a clear transition between staging systems and ensure consistency of UK data.

 

Breast

 

Endocrine system

 

Eye

 

Gastrointestinal tract

Liver

 

 

 

Gynaecological tract

Head and neck

 

Lung and thorax

Tissue pathway for non-neoplastic thoracic pathology

October 2024

 

 

Skin

Invasive squamous cell carcinoma

 

 

Urinary tract and testis